Vildagliptin

Evidence Level: L5

Predicted Indications: 9

Vildagliptin

Pharmacist Assessment Report

Vildagliptin: From Type 2 Diabetes Mellitus to Classic Stiff Person Syndrome

One-Sentence Summary

Vildagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for classic stiff person syndrome, but this is a model prediction only. There are currently 0 clinical trials and 0 publications supporting this direction.

Quick Overview

Item	Content
Original Indication	Type 2 diabetes mellitus
Predicted New Indication	Classic stiff person syndrome
TxGNN Prediction Score	0.9988
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Vildagliptin is a DPP-4 inhibitor. The compiled pharmacology data lists DPP-4 as its main target, along with DPP-8, DPP-9 and TRPV4. Its efficacy in type 2 diabetes is established. It raises incretin levels (GLP-1 and GIP), which supports glucose-dependent insulin secretion and reduces glucagon.

The data compiled for this report does not support a mechanistic link between this drug and classic stiff person syndrome. Stiff person syndrome is a rare autoimmune neurological disorder, often associated with anti-GAD65 antibodies. No established connection to DPP-4 inhibition was identified. The very high score from the TxGNN model (deep learning) (0.9988) may reflect similarities the model learned between related diseases, not biological evidence. It is not evidence of benefit. A closely related condition, focal stiff limb syndrome, received an identical score (0.9988) and also has no supporting evidence.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 13846R	Galvus	Tablet 50 mg (oral)	Not specified in the data compiled

Safety Considerations

Please refer to the TGA-approved Product Information (PI) for safety information. The data compiled for this report did not include label warnings, contraindications or drug-drug interactions for vildagliptin.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction rests on the score from the TxGNN model (deep learning) alone (Evidence Level L5). There are no clinical trials or publications, and no plausible mechanism linking DPP-4 inhibition to stiff person syndrome. The original mechanism of action data and the product safety information are also missing.

To proceed, the following is needed:

A credible mechanistic hypothesis connecting DPP-4 inhibition to the pathophysiology of stiff person syndrome, such as GAD65 autoimmunity or GABAergic dysfunction
Preclinical or case-level evidence in stiff person syndrome
Detailed mechanism of action data (MOA)
TGA Product Information warnings and contraindications for a safety review
The approved indication text for the ARTG entry

Note: In the data compiled, type 1 diabetes mellitus has substantially more support. This includes a completed Phase 2 randomised trial of rapamycin plus vildagliptin (NCT02803892, published as PMID 33124663) and several small mechanistic studies. It is rated L2, but the evidence is small and adjunctive, and vildagliptin is not approved for type 1 diabetes. If the aim is to prioritise repurposing opportunities for this drug, that indication may merit separate evaluation.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.